-
1 Comment
JW Lifescience Corporation is currently in a long term downtrend where the price is trading 3.4% below its 200 day moving average.
From a valuation standpoint, the stock is 81.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.6.
JW Lifescience Corporation's total revenue rose by 0.2% to $45B since the same quarter in the previous year.
Its net income has dropped by 216.6% to $-6B since the same quarter in the previous year.
Finally, its free cash flow grew by 947.6% to $19B since the same quarter in the previous year.
Based on the above factors, JW Lifescience Corporation gets an overall score of 3/5.
| Industry | Drug Manufacturers - Specialty & Generic |
|---|---|
| Exchange | KO |
| CurrencyCode | KRW |
| ISIN | KR7234080000 |
| Sector | Healthcare |
| Target Price | 18000 |
|---|---|
| Dividend Yield | 4.3% |
| Beta | 0.47 |
| Market Cap | 174B |
| PE Ratio | None |
JW Lifescience Corporation provides national infusion solutions in South Korea and internationally. The company offers basic intravenous fluid that comprises water, electrolytes, and glucose; nutrient infusion solution that consist of nutrients, such as amino acids, lipids, proteins, vitamins, and minerals; and special infusion solutions. The company was formerly known as JW Co. Ltd. and changed its name to JW Lifescience Corporation in April 2011. JW Lifescience Corporation was founded in 1994 and is based in Dangjin-si, South Korea.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 234080.KO using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
